NantHealth Inc (NASDAQ:NH) will team up with NantOmics to present findings of a joint research during this year’s American Society of Clinical Oncology’s anticipated Cancers Symposium. The research involved top-notch researchers from the respective companies. The researchers are tasked with seeking the understanding on the reason particular patients are generally non-responsive to targeted cancer therapies hinged on DNA genomic profiling.
Company’s Stock
The success of the collaboration may have meaningful results on both companies’ market positions. For instance as of this writing, NantHealth® closed the recent business day at $0.86 representing a 3.64% fall. The company currently boasts a market capitalization of $122.63 million.
Moving on, the presentation will be divided into two posters presented on two different days. The first session will cover individual biomarkers harvested from biopsies. The biomarkers may possess the potential to enhance therapies designed for prostate cancer patients.
The second poster is the findings of the research carried out in collaboration with scientists from the UC San Diego Health Moores Cancer Center. The findings illustrate possible cause of treatment non-responsiveness for patients with metastatic kidney, bladder, and prostate cancer. The presentation will show the clinical importance of examining inconsistency in DNA alterations as well as RNA expression.
Significance of the Research
According to Sandeep “Bobby” Reddy, MD, CMO at the NantHealth, “It is becoming clear that we must delve deeper into RNA expression, as well as identify key biomarkers to develop effective cancer treatments and therapies.” Bobby made the observation that some patients do not respond to targeted treatments based only on DNA genomic profiling thus warranting more studies into RNA expression. According to the joint team that conducted the studies, it is clinically necessary to carry out tests on RNA Expressions on individual biomarkers in order to eliminate the possibilities iof patients non-responsiveness during cancer testing.
The Genitourinary Cancers Symposium is a 3-day scientific fair featuring various leaders and physicians in the cancer care and research space seeking to treat and study GU malignancies.